Loading...
*  Efficacy of Pioglitazone on Microcirculation in Type 2 Diabetes Patients Treated With Insulin - Full Text View - ClinicalTrials...
Pioglitazone is a thiazolidinedione compound with a mode of action as a peroxisome proliferator-activated receptor gamma agonist. Activation of this receptor causes increased transcriptional activity at a number of locations that are important to carbohydrate and lipid (fat) metabolism. Insulin resistance is reversed by enhancing the action of insulin, thereby promoting glucose utilization in peripheral tissues, suppressing gluconeogenesis in the liver, and reducing lipolysis at the adipocyte.. In previous studies of pioglitazone, peripheral edema (swelling in the hands, feet, and legs) was reported as an adverse event more often in pioglitazone groups and appears to be a dose dependent phenomenon with pioglitazone. The incidence of peripheral edema in monotherapy studies was 3.2% in pioglitazone patients compared with 0.7% placebo patients and was reported more by females than males. This incidence was higher when pioglitazone was combined with sulphonylurea or insulin ...
  https://clinicaltrials.gov/ct2/show/NCT00676260
*  Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats | Gut
Aim: Peroxisome proliferator activated receptor γ (PPARγ) agonists have been shown to prevent hepatic fibrosis in rodents. We evaluated the therapeutic antifibrotic potential of the PPARγ agonist pioglitazone on established hepatic fibrosis.. Methods: Repeated injections of carbon tetrachloride (CCl4), a choline deficient diet, or bile duct ligation (BDL) were used to induce hepatic fibrosis in rats. Pioglitazone treatment was introduced at various time points. Therapeutic efficacy was assessed by comparison of the severity of hepatic fibrosis in pioglitazone treated versus untreated fibrotic controls.. Results: When introduced after two weeks of CCl4, pioglitazone reduced hepatic fibrosis, OH proline content, hepatic mRNA expression of collagen type I, and profibrotic genes, as well as the number of activated α smooth muscle actin positive hepatic stellate cells, compared with rats receiving CCl4 only, with no significant change in ...
  http://gut.bmj.com/content/55/7/1020
*  A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma - Full...
Background:. - Individuals who have severe asthma that is not easily controlled by current treatments are in need of new treatments to prevent potentially life-threatening asthma attacks. Experiments in mice have found that a medication called pioglitazone hydrochloride (Actos ), which is used to treat patients with diabetes, may be effective for treating severe asthma. Researchers are interested in determining whether Actos is effective in improving the quality of life in subjects with severe asthma who continue to have symptoms despite maximum standard medical therapy.. Objectives:. - To assess the effectiveness of pioglitazone hydrochloride as a treatment for patients with severe asthma that is not controlled by standard treatments.. Eligibility:. - Individuals between 18 and 75 years of age who have been diagnosed with and treated for severe asthma for at least 1 year.. Design:. ...
  https://clinicaltrials.gov/ct2/show/NCT00994175?term=refractory+asthma&rank=1
*  Pioglitazone Hydrochloride/ Gimeracil/Vecuronium Bromide CP/EP/USP
Pioglitazone Hydrochloride CAS: 112529-15-4 99% English name: Pioglitazone Hydrochloride Chinese Chemical name: (±) 5 - [[4 - [2 - (5 - ethyl - 2 - pyridyl) ethoxy] phenyl] methyl] -2,4 -thiazole
  http://www.sinogracechemical.com/sdp/1494470/4/pd/10475000-2734434/Pioglitazone_Hydrochloride_Gimeracil_Vecuronium_B.html
*  Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the...
Thiazolidinediones lower lipids, but it is unclear whether this is essential for their insulin-sensitizing action. We investigated relationships between lipid-lowering and insulin-sensitizing actions of a thiazolidinedione. Normal rats were pretreated with or without Pioglitazone (Pio, 3 mg/kg.d) for 2 wk. Insulin sensitivity was assessed by hyperinsulinemic-euglycemic clamp with elevation of free fatty acids (FFA) by Intralipid/heparin infusion over 6 h. In untreated rats insulin sensitivity decreased by 46% over 3-6 h of elevated FFA, whereas it remained normal but with a 50% increase in FFA clearance in Pio-treated rats. After matching plasma FFA, insulin sensitivity was still partially (30%) protected in Pio-treated rats, substantially by maintaining insulin suppressibility of hepatic glucose output. This was associated with lower hepatic long-chain acyl-coenzyme A. Plasma adiponectin was increased 2-fold in Pio-treated rats and was negatively correlated with hepatic glucose output (r2 = ...
  https://www.garvan.org.au/research/publications/1621
*  Effect of Rosiglitazone Treatment on Plaque Inflammation and Collagen Content in Nondiabetic Patients | Arteriosclerosis,...
The present randomized, placebo-controlled, single-blind trial demonstrates that 4 weeks of treatment with rosiglitazone reduces inflammatory cell composition and cell activation in carotid artery specimen of nondiabetic patients. Moreover, rosiglitazone increased collagen content in the plaque, suggesting that TZD treatment renders these plaques more stable and less vulnerable.. Previous studies have shown that TZDs exhibit antiinflammatory and antiatherogenic properties in vascular cells in vitro, and data from animal models of arteriosclerosis demonstrated a reduction in lesion development on TZD treatment.8 Moreover, clinical studies have shown that TZDs reduce serum levels of inflammatory arteriosclerosis markers in treated patients11,12,22 and induce beneficial morphological changes in the vessel wall by reducing IMT of the carotid artery13 as well as neointima formation after coronary stent implantation.15,16 The present study extends our knowledge on the effect of TZDs in the vessel wall ...
  http://atvb.ahajournals.org/content/26/4/845
*  Caffeine Enhances Endothelial Repair by an AMPK-Dependent Mechanism | Arteriosclerosis, Thrombosis, and Vascular Biology
Our study finds that coffee consumption or ex vivo treatment of cells with caffeine significantly improves migration of ECs and EPCs by an AMPK-dependent mechanism. Importantly, AMPK also contributed to the enhanced reendothelialization induced by caffeine in vivo. The beneficial influence of caffeine on reendothelialization seen in the mouse model could be explained by both migration of mature ECs as well as attachment of circulating EPCs, accelerating recovery of the endothelial monolayer. Several studies have documented the fundamental role of EPCs in the healing process of vascular endothelium alone,26 after mobilization with GM-colony stimulating factor (CSF),27 erythropoietin,28 or pretreatment with statins,3 estrogen29,30 or the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.31 So far, two studies have investigated a potential role of AMPK for migration at least in mature ECs. Nagata et al have shown that overexpression of a dominant-negative ...
  http://atvb.ahajournals.org/content/28/11/1967
*  Caffeine Enhances Endothelial Repair by an AMPK-Dependent Mechanism | Arteriosclerosis, Thrombosis, and Vascular Biology
Our study finds that coffee consumption or ex vivo treatment of cells with caffeine significantly improves migration of ECs and EPCs by an AMPK-dependent mechanism. Importantly, AMPK also contributed to the enhanced reendothelialization induced by caffeine in vivo. The beneficial influence of caffeine on reendothelialization seen in the mouse model could be explained by both migration of mature ECs as well as attachment of circulating EPCs, accelerating recovery of the endothelial monolayer. Several studies have documented the fundamental role of EPCs in the healing process of vascular endothelium alone,26 after mobilization with GM-colony stimulating factor (CSF),27 erythropoietin,28 or pretreatment with statins,3 estrogen29,30 or the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone.31 So far, two studies have investigated a potential role of AMPK for migration at least in mature ECs. Nagata et al have shown that overexpression of a dominant-negative ...
  http://atvb.ahajournals.org/content/28/11/1967.full
*  Pioglitazone for Lung Cancer Chemoprevention - Full Text View - ClinicalTrials.gov
Patients will be randomized to receive either pioglitazone or placebo. Pioglitazone hydrochloride, a thiazolidinedione antidiabetic agent and a potent peroxisome proliferator-. activated receptor-gamma agonist. It is FDA approved for the treatment of Type II diabetes. It has been previously administered to non-diabetic subjects. The most common side effect of pioglitazone is fluid retention and modest weight gain. There is a potential risk that pioglitazone may cause an elevation in liver enzymes and more serious hepatotoxicity (rare). There is risk of edema and weight gain associated with pioglitazone therapy. 5% experienced peripheral edema in clinical trials. fluid retention may result in new onset heart failure or exacerbation of existing heart failure. Small risk of hypoglycemia, anemia, myalgia, bone fracture, headache, and macular retinal edema exists. There is insufficient information to confirm its safety in Pregnancy/Breastfeeding. Bladder cancer is more serious ...
  https://clinicaltrials.gov/ct2/show/NCT00780234?term=cardiac+CT+OR+CAT+scan+OR+coronary+artery+scan&recr=Open&fund=01&rank=14
*  Pioglitazone for Lung Cancer Chemoprevention - Tabular View - ClinicalTrials.gov
Patients will be randomized to receive either pioglitazone or placebo. Pioglitazone hydrochloride, a thiazolidinedione antidiabetic agent and a potent peroxisome proliferator-. activated receptor-gamma agonist. It is FDA approved for the treatment of Type II diabetes. It has been previously administered to non-diabetic subjects. The most common side effect of pioglitazone is fluid retention and modest weight gain. There is a potential risk that pioglitazone may cause an elevation in liver enzymes and more serious hepatotoxicity (rare). There is risk of edema and weight gain associated with pioglitazone therapy. 5% experienced peripheral edema in clinical trials. fluid retention may result in new onset heart failure or exacerbation of existing heart failure. Small risk of hypoglycemia, anemia, myalgia, bone fracture, headache, and macular retinal edema exists. There is insufficient information to confirm its safety in Pregnancy/Breastfeeding. Bladder cancer is more serious ...
  https://clinicaltrials.gov/ct2/show/record/NCT00780234?term=%22Type+2+Diabetes%22&lup_s=11%2F28%2F2013&lup_d=14&show_rss=Y&sel_rss=mod14
*  IRIS Trial Shows Decreased Risk of Stroke and MI Among Insulin-Resistant Patients Treated With Pioglitazone - American College...
Treatment with pioglitazone - an insulin-sensitizing drug in the thiazolidinedione class - may result in a decreased risk of stroke and myocardial infarction (MI) in patients without diabetes who have insulin resistance plus a recent history of ischemic stroke or transient ischemic attack (TIA), according to results of the IRIS Trial presented Feb. 17 at the International Stroke Conference and simultaneously published in the New England Journal of Medicine. The multicenter, double-blind trial randomly assigned either pioglitazone (target dose 45 mg) or a placebo to 3,876 patients who had recently had ischemic stroke or TIA. A primary outcome (fatal or non-fatal stroke or MI) occurred in 9 percent of patients who received pioglitazone and in 11.8 percent of patients who received the placebo. In addition, the rate of progression to diabetes was lower in the pioglitazone group than in the placebo group.. However, results also showed that the patients in the pioglitazone group experienced higher ...
  http://www.acc.org/latest-in-cardiology/articles/2016/02/17/16/01/iris-trial-shows-decreased-risk-of-stroke-and-mi-among-insulin-resistant-patients-treated-with-pioglitazone
*  Study to Assess the Benefit and Safety of Rosiglitazone in Preventing Atherosclerosis Progression After Coronary Artery Bypass...
The primary endpoint, saphenous vein graft plaque volume, increased 0.9% in the rosiglitazone group versus 2.8% in the placebo group (p = 0.22). Body weight increased 3 kg in the rosiglitazone group (p = 0.02). Fasting glucose was 116 mg/dl in the rosiglitazone group and 134 mg/dl in the placebo group (p < 0.0001), and high-density lipoprotein cholesterol was 45 mg/dl and 42 mg/dl (p = 0.0032), respectively. There were no deaths in either group; 0 versus 1 myocardial infarction, 1 versus 1 stroke, and 0 versus 2 transient ischemic attacks, for rosiglitizone versus placebo, respectively. ...
  http://www.acc.org/latest-in-cardiology/clinical-trials/2010/02/23/19/26/victorynbsp8212nbsppresented-at-scaiacc-i2-summitacc-2008
*  Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. - Oxford...
Obesity is associated with risk factors for cardiovascular disease, including insulin resistance, and can lead to cardiac hypertrophy and congestive heart failure. Here, we used the insulin-sensitizing agent rosiglitazone to investigate the cellular mechanisms linking insulin resistance in the obese Zucker rat heart with increased susceptibility to ischemic injury. Rats were treated for 7 or 14 days with 3 mg/kg per os rosiglitazone. Hearts were isolated and perfused before and during insulin stimulation or during 32 min low-flow ischemia at 0.3 ml small middle dot min(-1) small middle dot grams wet wt(-1) and reperfusion. D[2-(3)H]glucose was used as a tracer of glucose uptake, and phosphorus-31 nuclear magnetic resonance spectroscopy was used to follow energetics during ischemia. At 12 months of age, obese rat hearts were insulin resistant with decreased GLUT4 protein expression. During ischemia, glucose uptake was lower and depletion of ATP was greater in obese rat hearts, thereby significantly
  https://www.neuroscience.ox.ac.uk/publications/106228
*  Pioglitazone Prevents Hypertension and Reduces Oxidative Stress in Diet-Induced Obesity | Hypertension
In this study, we showed that pioglitazone treatment prevented the development of hypertension and renal oxidative stress in a rat model of diet-induced obesity. Also, our results indicate that compared with vitamin E, a well-known antioxidant, pioglitazone is more efficient in reducing BP and increasing sodium excretion in obese versus lean rats, while being equally efficient in reducing urinary isoprostanes, kidney TBARS, and HNE adducts. One possible explanation for these different effects is the ability of pioglitazone, as opposed to vitamin E, to increase renal NOS expression and NOx excretion in treated OP rats. In addition, pioglitazone, but not vitamin E treatment, significantly reduced expression of p47phox and gp91phox in OP rats, suggesting that both a reduction in oxidative stress and an improvement in NO production/bioavailability are important in efficiently reducing BP in this model.. Thiazolidinediones are known to exert pleiotropic actions both in vivo and ...
  http://hyper.ahajournals.org/content/43/1/48
*  Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose. - Full Text View -...
The World Health Organization has estimated that 30% of all women aged over 50 years (postmenopausal) have osteoporosis according to a definition of Bone Mineral Density at any site being more than 2.5 standard deviations below the mean for young healthy adult women.. A known risk factor for development of osteoporosis and fracture is diabetes mellitus, with correlations to duration of disease and poor glycemic control.. Pioglitazone is a thiazolidinedione developed by Takeda Pharmaceuticals for the treatment of type 2 diabetes. Preclinical studies to date on the bone effects of thiazolidinediones have not clearly identified a mechanism of bone loss. While there is evidence of increased bone fractures in postmenopausal diabetic females treated with a thiazolidinedione, the mechanism is not known. Initial studies with thiazolidinediones in humans have focused on short term exposure (12 to 14 weeks) and non-diabetic females. These studies have shown acute ...
  https://clinicaltrials.gov/ct2/show/NCT00708175
*  Die Bedeutung von "Peroxisome Proliferator-Activated Receptors" in der Pathogenese von Gefäßwandläsionen und ihr Einfluß auf...
Migration and proliferation of vascular cells not only play an important role in the pathogenesis of atherosclerotic lesion formation, but also contribute to restenosis after therapeutic angioplasty. Therefore, pharmacological strategies for the prevention and/or treatment of atherosclerotic and restenotic vascular lesions are of great clinical interest. This involves substances that can be locally administered via stents, as well as agents that are already in clinical use for the treatment of metabolic risk factors. Among the latter, antidiabetic thiazolidinediones which function as ligands for the "peroxisome proliferator-activated receptor gamma" (PPARg), have been identified as promising drugs to target vascular lesion formation. PPARs constitute a group of novel regulators of gene expression, that exert several vascular effects. We report that vascular smooth muscle cell proliferation and migration is ...
  https://edoc.hu-berlin.de/handle/18452/14508
*  A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors
Twenty-three RCTs were included: 10 of pioglitazone (n=3,305) and 13 of rosiglitazone (n=5,245).. Blood glucose level.. Pioglitazone, when used as monotherapy, significantly reduced HbA1c levels by -0.99% (95% CI: -1.32, -0.66) at a dose of 30 mg/day and by -1.21% (95% CI: -1.79, -0.62) at 45 mg/day, compared with placebo. When used in combination with other antidiabetic agents, pioglitazone (30 and 45 mg/day) significantly reduced HbA1c levels by -1.16% (95% CI: -1.41, -0.90) and -1.56% (95% CI: -1.96, -1.16), respectively, in comparison with placebo.. Rosiglitazone, when used as monotherapy, significantly reduced HbA1c levels by -0.90% (95% CI: -1.42, -0.38) at a dose of 4 mg/day and by -1.50% (95% CI: -1.75, -1.24) at 8 mg/day. When used in combination with other antidiabetic agents, rosiglitazone (4 and 8 mg/day) significantly reduced HbA1c levels by -1.05% (95% CI: -1.19, -0.90) and -1.26% (95% CI: -1.48, -1.04), respectively, in comparison with placebo.. FBG.. Pioglitazone, when used as ...
  http://www.crd.york.ac.uk/crdweb/ShowRecord.asp?LinkFrom=OAI&ID=12004008760
*  thiazolidinediones (TZDs)
Certain Type 2 diabetes drugs, known as thiazolidinediones (TZDs), are recognized as having the extra benefit of lowering blood pressure. Recent research seems to have come up with an explanation for why this is. The research has shown that the molecule peroxisome proliferator-activated receptor Ó (PPARÓ) "stands at the crossroads of metabolic and cardiovascular diseases… Continue reading →. ...
  https://www.defeatdiabetes.org/tag/thiazolidinediones-tzds/
*  Role of PPAR-γ Agonist Thiazolidinediones in Treatment of Pre-Diabetic and Diabetic Individuals: A Cardiovascular Perspective...
Title: Role of PPAR-γ Agonist Thiazolidinediones in Treatment of Pre-Diabetic and Diabetic Individuals: A Cardiovascular Perspective. VOLUME: 5 ISSUE: 5. Author(s):Rupal Dumasia, Kim A. Eagle, Eva Kline-Rogers, Niquole May, Leslie Cho and Debabrata Mukherjee. Affiliation:Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, 900 S Limestone,326 Wethington Building, Lexington, KY 40536-0200, USA.. Keywords:type diabetes mellitus, hyperglycemia, insulin sensitizing agents, vascular complications, insulin resistance, anti-atherosclerotic. Abstract: The peroxisome proliferator-activated receptors (PPARs) are nuclear fatty acid receptors, which contain a type II zinc finger DNA binding motif and a hydrophobic ligand binding pocket. These receptors are thought to play an important role in metabolic diseases such as obesity, insulin resistance, and coronary artery disease. Three subtypes of PPAR ...
  http://www.eurekaselect.com/90141
*  Pioglitazone Sale - Purchase Generic Pioglitazone Online Canada
Pioglitazone purchase now payment australia, Price of pioglitazone at target, Pioglitazone price perth, Order pioglitazone reviews, Purchase pioglitazone for me, Top pioglitazone store online, Order generic pioglitazone shop usa, Buy pioglitazone pill
  http://pioglitazone.irfa.info
*  These highlights do not include all the information needed to use pioglitazone tablets safely and effectively. See full...
Following once daily administration of pioglitazone tablets, steady-state serum concentrations of both pioglitazone and its major active metabolites, M-III (keto derivative of pioglitazone) and M-IV (hydroxyl derivative of pioglitazone), are achieved within seven days. At steady-state, M-III and M-IV reach serum concentrations equal to or greater than that of pioglitazone. At steady-state, in both healthy volunteers and patients with type 2 diabetes, pioglitazone comprises approximately 30% to 50% of the peak total pioglitazone serum concentrations (pioglitazone plus active metabolites) and 20% to 25% of the total AUC.. Maximum serum concentration (Cmax), AUC, and trough serum concentrations (Cmin) for pioglitazone and M-III and M-IV, increased proportionally with administered doses of 15 mg and 30 mg per day.. Absorption: Following oral administration of pioglitazone Tmax of pioglitazone was within two hours. Food delays the Tmax to three to four hours but does not alter the extent of ...
  https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ccf82737-754b-472e-a9bb-961fd1a3c307&type=display
*  PROVIDENCE:Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With Coronary Lesions - Full Text...
We hypothesize that the combination of the thin-strut MULTI-LINK (i.e. VISION(tm) and/or MINI-VISION(tm)) stent and pharmacologic therapy with the oral PPAR-gamma agonist rosiglitazone will significantly reduce restenosis after intracoronary stenting in type 2 diabetic patients. This approach would present a more effective and economical alternative to the use of drug-eluting stents to reduce stent restenosis ...
  https://clinicaltrials.gov/ct2/show/study/NCT00116792?view=record
*  PROVIDENCE:Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With Coronary Lesions - Full Text...
We hypothesize that the combination of the thin-strut MULTI-LINK (i.e. VISION(tm) and/or MINI-VISION(tm)) stent and pharmacologic therapy with the oral PPAR-gamma agonist rosiglitazone will significantly reduce restenosis after intracoronary stenting in type 2 diabetic patients. This approach would present a more effective and economical alternative to the use of drug-eluting stents to reduce stent restenosis ...
  https://clinicaltrials.gov/ct2/show/study/NCT00116792?view=results